Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight
• UBS Downgrades Banco Santander Brasil SA (SANB11:BZ) (BSBR) to Neutral
• Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight